Incidence of pNeumonia and Related ConseqUences in Nursing Home Residents (INCUR)
Incidence of pNeumonia and Related ConseqUences in Nursing Home
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Toulouse, France
- University Hospital Toulouse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Groups Iso-Resources (GIR) ranging between 5 (included) and 2 (included)
- Ability and willingness to participate to the study and to provide informed consent
- Agreement with the patient's physician about the enrolment to the study
Exclusion Criteria:
- Refusal of the EHPAD to participate
- Patients with severe disability (GIR 1)
- Patients with no evidence of functional impairment (GIR 6)
- Patients living in the participating EHPAD for less than 30 days since the baseline study visit
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of pneumonia
Time Frame: months 12
|
Estimate the incidence of pneumonia events in a sample of 800 older patients living in 30 EHPADs over a period of 12 months
|
months 12
|
|
healthcare costs
Time Frame: months 12
|
To compare the healthcare costs of participants experiencing a pneumonia event versus those who will not in a random sample of 800 older patients living in 30 EHPADs over a period of 12 month
|
months 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mortality risk
Time Frame: Months 12
|
To calculate the mortality risk in a random sample of 800 EHPAD older patients according to the presence/absence of a pneumonia event occurred during a follow-up period of 12 months
|
Months 12
|
|
Physical Function
Time Frame: Months 12
|
To measure the physical function modifications experienced by a random sample of 800 EHPAD older patients according to the presence/absence of a pneumonia event occurred during a follow-up period of 12 months
|
Months 12
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Mateo Cesari, MD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11 280 03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumonia
-
NCT00610324CompletedNosocomial Pneumonia | Healthcare-Associated Pneumonia | Aspiration Pneumonia | Ventilator-Associated Pneumonia
-
NCT03006679WithdrawnHospital-Acquired Bacterial Pneumonia | Ventilator-Associated Bacterial Pneumonia | Hospital-Acquired Pneumonia | Ventilator-Associated Pneumonia
-
NCT06168734WithdrawnHospital-acquired Pneumonia | Ventilator-associated Pneumonia
-
NCT07354425CompletedPneumococcal Pneumonia | Community Acquired Pneumonia (CAP)
-
NCT04952337UnknownCOVID-19 | Bacterial Pneumonia | Viral Pneumonia | Pneumonia Due to Streptococcus Pneumoniae | Pneumonia Due to H. Influenzae | Pneumonia, Organism Unspecified | Pneumonia in Diseases Classified Elsewhere | Pneumonia Due to Other Specified Infectious Organisms
-
NCT03348579CompletedPneumonia | Sepsis | Ventilator-Associated Pneumonia | Hospital Acquired Pneumonia
-
NCT01808092CompletedVentilator-associated Pneumonia (VAP) | Nosocomial Pneumonia (NP)
-
NCT00543608TerminatedHospital-Acquired Pneumonia | Ventilator-Associated Pneumonia | Health-Care-Associated Pneumonia
-
NCT02203110UnknownCommunity Acquired Pneumonia | Ventilator Associated Pneumonia | Hospital Acquired Pneumonia
-
NCT06430008Enrolling by invitationSialic Acid | Superoxide Dismutase | Lipid Pneumonia
Clinical Trials on Data collection on pneumonia events
-
NCT05021575Completed
-
NCT01195558RecruitingSleep-wake Disorder in Blind Individuals
-
NCT04937621CompletedArrhythmia | SARS-CoV-2 Infection
-
NCT03796741CompletedChronic Ischemic Heart Disease
-
NCT06878105RecruitingAnemia | Coagulopathy
-
NCT05639348CompletedPostoperative Delirium (POD)
-
NCT01058122CompletedAdverse Drug Reactions